Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Rises By 24.0%

Fractyl Health, Inc. (NASDAQ:GUTS) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, a growth of 24.0% from the December 15th total of 9,589,100 shares. Based on an average trading volume of 3,196,474 shares, the short-interest ratio is presently 3.7 days. Approximately 11.7% of the shares of the company are short sold. Approximately 11.7% of the shares of the company are short sold. Based on an average trading volume of 3,196,474 shares, the short-interest ratio is presently 3.7 days.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Friday, December 19th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

Fractyl Health Stock Performance

Fractyl Health stock traded down $0.09 during midday trading on Tuesday, reaching $1.83. 1,277,004 shares of the stock were exchanged, compared to its average volume of 2,834,380. The company’s fifty day moving average is $1.91 and its 200-day moving average is $1.51. The firm has a market cap of $250.10 million, a PE ratio of -0.80 and a beta of 1.62. Fractyl Health has a 52 week low of $0.83 and a 52 week high of $3.03.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, sell-side analysts anticipate that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Fractyl Health

A number of large investors have recently modified their holdings of GUTS. Catalyst Funds Management Pty Ltd purchased a new position in shares of Fractyl Health during the second quarter worth about $26,000. Jane Street Group LLC bought a new stake in Fractyl Health during the second quarter valued at approximately $31,000. FNY Investment Advisers LLC bought a new stake in Fractyl Health during the third quarter valued at approximately $31,000. Scientech Research LLC bought a new position in shares of Fractyl Health in the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter valued at $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.